accuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.
Company profile
Ticker
ARAY
Exchange
Website
CEO
Joshua Levine
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Accuray International SARL • Accuray Europe SAS • Accuray UK, Ltd. • Accuray Asia Ltd. • Accuray Japan K.K. • Accuray Korea Limited Company • Accuray Medical Equipment (India) Private Limited • Accuray Medical Equipment (Rus) LLC. • Accuray Medical Equipment GmbH • Accuray Medical Equipment (Canada) Ltd. ...
IRS number
770268932
ARAY stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
8 May 24
8-K
Accuray Reports Fiscal 2024 Third Quarter Financial Results
1 May 24
10-Q
2024 Q2
Quarterly report
7 Feb 24
8-K
Accuray Reports Fiscal 2024 Second Quarter Financial Results
31 Jan 24
S-8
Registration of securities for employees
30 Nov 23
8-K
Departure of Directors or Certain Officers
15 Nov 23
10-Q
2024 Q1
Quarterly report
7 Nov 23
8-K
Accuray Reports Fiscal 2024 First Quarter Financial Results
7 Nov 23
8-K
Cost Associated with Exit or Disposal Activities
25 Oct 23
8-K
Regulation FD Disclosure
3 Oct 23
Transcripts
ARAY
Earnings call transcript
2024 Q3
1 May 24
ARAY
Earnings call transcript
2024 Q2
31 Jan 24
ARAY
Earnings call transcript
2024 Q1
7 Nov 23
ARAY
Earnings call transcript
2023 Q4
9 Aug 23
ARAY
Earnings call transcript
2023 Q2
9 Aug 23
ARAY
Earnings call transcript
2023 Q3
26 Apr 23
ARAY
Earnings call transcript
2023 Q2
1 Feb 23
ARAY
Earnings call transcript
2023 Q1
3 Nov 22
ARAY
Earnings call transcript
2022 Q4
11 Aug 22
ARAY
Earnings call transcript
2022 Q3
28 Apr 22
Latest ownership filings
4
Michael Hoge
5 Mar 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Archon Capital Management LLC
13 Feb 24
SC 13G/A
Neuberger Berman Group LLC
12 Feb 24
SC 13G
BlackRock Inc.
25 Jan 24
4
Ali Pervaiz
5 Jan 24
4
GIna Corradetti
5 Jan 24
4
Robert Kill
4 Dec 23
4
Patrick Spine
4 Dec 23
4
Suzanne C Winter
4 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 78.69 mm | 78.69 mm | 78.69 mm | 78.69 mm | 78.69 mm | 78.69 mm |
Cash burn (monthly) | 4.17 mm | 308.25 k | (no burn) | (no burn) | 2.86 mm | (no burn) |
Cash used (since last report) | 30.67 mm | 2.27 mm | n/a | n/a | 21.06 mm | n/a |
Cash remaining | 48.02 mm | 76.42 mm | n/a | n/a | 57.63 mm | n/a |
Runway (months of cash) | 11.5 | 247.9 | n/a | n/a | 20.1 | n/a |
Institutional ownership, Q4 2023
39.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 88 |
Opened positions | 13 |
Closed positions | 42 |
Increased positions | 29 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 86.16 bn |
Total shares | 39.51 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Archon Capital Management | 6.51 mm | $18.43 bn |
Neuberger Berman | 5.50 mm | $0.00 |
Royce & Associates | 3.23 mm | $9.15 bn |
Renaissance Technologies | 2.87 mm | $8.11 mm |
Heartland Advisors | 2.86 mm | $8.09 bn |
Wellington Management | 1.82 mm | $5.15 bn |
Dimensional Fund Advisors | 1.79 mm | $5.05 bn |
STT State Street | 1.72 mm | $4.87 bn |
Foundry Partners | 1.47 mm | $4.16 bn |
DAFNA Capital Management | 1.22 mm | $3.46 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Michael Hoge | Common Stock | Sell | Dispose S | No | No | 2.59 | 11,991 | 31.06 k | 390,208 |
3 Jan 24 | Ali Pervaiz | Common Stock | Sell | Dispose S | No | No | 2.7411 | 2,116 | 5.80 k | 402,743 |
3 Jan 24 | GIna Corradetti | Common Stock | Sell | Dispose S | No | No | 2.7411 | 14,129 | 38.73 k | 196,138 |
30 Nov 23 | Mika Nishimura | Common Stock | Grant | Acquire A | No | No | 0 | 56,603 | 0.00 | 156,056 |
30 Nov 23 | Beverly A Huss | Common Stock | Grant | Acquire A | No | No | 0 | 56,603 | 0.00 | 210,004 |
News
12 Health Care Stocks Moving In Thursday's Intraday Session
2 May 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
2 May 24
Accuray Q3 2024 GAAP EPS $(0.06) Misses $(0.01) Estimate, Sales $101.132M Miss $113.649M Estimate
1 May 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
1 May 24
Roth MKM Initiates Coverage On Accuray with Buy Rating, Announces Price Target of $9
13 Feb 24
Press releases
Accuray Reports Fiscal 2024 Third Quarter Financial Results
1 May 24
Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024
25 Apr 24
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
18 Apr 24
Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
17 Apr 24
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System
26 Mar 24